ARCA Biopharma Performance
The firm owns a Beta (Systematic Risk) of -2.7, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning ARCA Biopharma are expected to decrease by larger amounts. On the other hand, during market turmoil, ARCA Biopharma is expected to outperform it. ARCA Biopharma at this time owns a risk of 0.0%. Please confirm ARCA Biopharma standard deviation, as well as the relationship between the maximum drawdown and kurtosis , to decide if ARCA Biopharma will be following its current price history.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days ARCA Biopharma has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy forward indicators, ARCA Biopharma is not utilizing all of its potentials. The latest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 42.4 M |
ARCA |
ARCA Biopharma Relative Risk vs. Return Landscape
If you would invest (100.00) in ARCA Biopharma on September 25, 2024 and sell it today you would earn a total of 100.00 from holding ARCA Biopharma or generate -100.0% return on investment over 90 days. ARCA Biopharma is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than ARCA, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
ARCA Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for ARCA Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as ARCA Biopharma, and traders can use it to determine the average amount a ARCA Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ABIO |
Based on monthly moving average ARCA Biopharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of ARCA Biopharma by adding ARCA Biopharma to a well-diversified portfolio.
ARCA Biopharma Fundamentals Growth
ARCA Stock prices reflect investors' perceptions of the future prospects and financial health of ARCA Biopharma, and ARCA Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on ARCA Stock performance.
| Return On Equity | -0.2 | |||
| Return On Asset | -0.14 | |||
| Current Valuation | 393.23 M | |||
| Shares Outstanding | 14.51 M | |||
| Price To Earning | (0.63) X | |||
| Price To Book | 13.09 X | |||
| EBITDA | (7.3 M) | |||
| Cash And Equivalents | 46.44 M | |||
| Cash Per Share | 3.22 X | |||
| Total Debt | 280 K | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 2.25 X | |||
| Cash Flow From Operations | (5.01 M) | |||
| Earnings Per Share | (5.88) X | |||
| Total Asset | 37.86 M | |||
| Retained Earnings | (188.74 M) | |||
| Current Asset | 5.88 M | |||
| Current Liabilities | 26.61 M | |||
About ARCA Biopharma Performance
By examining ARCA Biopharma's fundamental ratios, stakeholders can obtain critical insights into ARCA Biopharma's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that ARCA Biopharma is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
ARCA biopharma, Inc., a clinical-stage biopharmaceutical company, develops and commercializes genetically targeted therapies for cardiovascular diseases. The company was incorporated in 2004 and is headquartered in Westminster, Colorado. Arca Biopharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 17 people.Things to note about ARCA Biopharma performance evaluation
Checking the ongoing alerts about ARCA Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for ARCA Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| ARCA Biopharma is now traded under the symbol ORKA. Please update your portfolios or report it if you believe this is an error. Report It! | |
| ARCA Biopharma is not yet fully synchronised with the market data | |
| ARCA Biopharma has some characteristics of a very speculative penny stock | |
| ARCA Biopharma has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (5.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| ARCA Biopharma currently holds about 46.44 M in cash with (5.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.22. | |
| Over 99.0% of the company shares are held by institutions such as insurance companies |
- Analyzing ARCA Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether ARCA Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining ARCA Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating ARCA Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of ARCA Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of ARCA Biopharma's stock. These opinions can provide insight into ARCA Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Other Consideration for investing in ARCA Stock
If you are still planning to invest in ARCA Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ARCA Biopharma's history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |